No Photo Available

Last Update

2008-08-02T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Thomas Rinderknecht?

Dr. Thomas M. Rinderknecht

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Partner

Rinderknecht Klein & Stadelhofer

Senior Partner

Rinderknecht Klein & Stadelhofer

Owner

RKS Rinderknecht & Burger

Position

Board Of Directors

Affiliations

Board Member
Antares Pharma , Inc.

Legal Advisor On Various Matters
Antares Pharma , Inc.

Board Member
Permatec

Member
Audit Committee

Education

law degrees

University of Zurich

law degrees

University of Munich

law degrees

Switzerland

Web References (24 Total References)


Glycart Biotechnology - Board of Directors

www.glycart.com [cached]

Thomas M. Rinderknecht, PhD (non-exec. Director) is senior partner of law firm Rinderknecht Klein & Stadelhofer, Zurich.He holds a doctor iuris degree of the University of Zurich, studied law in Zurich and Munich, practiced since 1982 as lawyer in international law firms in Switzerland and the United States, served and/or serves on various boards of public and private companies in the fields of pharmaceutical, biotech, publishing, media, financing and other business areas.


The Compensation Committee, consisting of ...

www.sec.gov [cached]

The Compensation Committee, consisting of Mr. Clark, Dr. Harrison and Dr. Thomas Rinderknecht (until his resignation from the board on December 13, 2002), met informally during 2002 with compensation actions being considered by the full Board.

...
No member of the Compensation Committee was, during the 2002 fiscal year or previously, an officer or employee of ANTARES PHARMA INC, nor did any member have any relationship or transaction with us which is required to be reported under Item 402(k) or Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Up until his resignation from our board on December 13, 2002, Dr. Rinderknecht served as a member of our Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal adviser on various matters.
...
The members of the Compensation Committee are James Clark, Roger Harrison and Dr. Thomas Rinderknecht (until his resignation from our board on December 13, 2002).
...
2002. Dr. Thomas Rinderknecht, one of our board members until his resignation on December 13, 2002, is a partner in the firm of Rinderknecht Klein and Stadelhofer.


Dr. Thomas ...

www.sec.gov [cached]

Dr. Thomas Rinderknecht

...
Dr. Rinderknecht joined the Board of Directors in January 2001 and served on its Audit Committee.He has also been a director of Permatec since its founding in June 1997.Dr. Rinderknecht has been a partner in the firm of Rinderknecht Klein & Stadelhofer in Zurich, Switzerland since 1985 and has been practicing commercial law in Europe since 1982.He holds law degrees from the University of Zurich, Switzerland and the University of Munich, Germany. None of the above directors are related to one another or to any executive officers of our Company. Information Concerning the Board of Directors The Board of Directors met five times during 2001 and acted by written action two times during 2001.The Board of Directors has an Audit and a Compensation Committee. The Audit Committee consisted of Mr. Evenstad, Dr. Philippe Dro and Dr. Thomas Rinderknecht and met three times during 2001.
...
The Compensation Committee, consisting of Mr. Clark, Dr. Gonella and Dr. Rinderknecht, met informally during 2001 with compensation actions being considered by the full Board.
...
No member of the Compensation Committee was, during the 2001 fiscal year or previously, an officer or employee of ANTARES PHARMA INC /MN/, nor did any member have any relationship or transaction with ANTARES PHARMA INC /MN/ which is required to be reported under Item 402(k) or Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Dr. Rinderknecht served as a member of both the Audit Committee and the Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal adviser on various matters.ANTARES PHARMA INC /MN/ recognized expenses of $97,292 for services provided by Rinderknecht, Klein & Stadelhofer in 2001. REPORT OF THE AUDIT COMMITTEE The Audit Committee reviews our financial reporting process on behalf of the Board of Directors.The members of the Audit Committee are Mr. Kenneth Evenstad, Dr. Philippe Dro and Dr. Thomas Rinderknecht.
...
Dr. Thomas Rinderknecht
...
The members of the Compensation Committee are James Clark, Dr. Jacques Gonella and Dr. Thomas Rinderknecht.
...
Dr. Thomas Rinderknecht
...
Dr. Thomas Rinderknecht (8)


Kenneth Evanstad and Thomas ...

www.sec.gov [cached]

Kenneth Evanstad and Thomas Rinderknecht resigned from the board of directors on August 30, 2002, and December 13, 2002, respectively.

...
The Compensation Committee, consisting of Mr. Clark, Dr. Harrison and Dr. Rinderknecht, met informally during 2002 with compensation actions being considered by the full Board.
...
No member of the Compensation Committee was, during the 2002 fiscal year or previously, an officer or employee of ANTARES PHARMA INC, nor did any member have any relationship or transaction with ANTARES PHARMA INC which is required to be reported under Item 402(k) of Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Dr. Rinderknecht served as a member of both the Audit Committee and the Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal advisor on various matters.


Dr. Thomas Rinderknecht 47 ...

www.sec.gov [cached]

Dr. Thomas Rinderknecht 47 Dr. Rinderknecht joined the Board of Directors in January 2001 and serves on its Compensation Committee.He also served on the Audit Committee until March 14, 2002.He has also been a director of Permatec since its founding in June 1997.Dr. Rinderknecht has been a partner in the firm of Rinderknecht Klein & Stadelhofer in Zurich, Switzerland since 1985, and has been practicing commercial law in Europe since 1982.He holds law degrees from the University of Zurich, Switzerland and the University of Munich, Germany.

...
The Audit Committee, consisting of Mr. Evenstad, Dr. Philippe Dro and Dr. Thomas Rinderknecht met three times during 2001.
...
The Compensation Committee, consisting of Mr. Clark, Dr. Gonella and Dr. Rinderknecht, met informally during 2001 with compensation actions being considered by the full Board.
...
No member of the Compensation Committee was, during the 2001 fiscal year or previously, an officer or employee of ANTARES PHARMA INC, nor did any member have any relationship or transaction with ANTARES PHARMA INC which is required to be reported under Item 402(k) of Regulation S-K under the Securities Exchange Act of 1934, as amended, except for Dr. Rinderknecht.Dr. Rinderknecht served as a member of both the Audit Committee and the Compensation Committee and his law firm, Rinderknecht, Klein & Stadelhofer, of which he is a principle, also served as legal advisor on various matters.ANTARES PHARMA INC recognized expenses of $97,292 for services provided by Rinderknecht, Klein & Stadelhofer in 2001. Section 16(a) Beneficial Ownership Reporting Compliance Section 16 (a) of the Securities Exchange Act of 1934 requires the Company's directors, certain officers and persons who own more than ten percent of a registered class of ANTARES PHARMA INC's equity securities, to file reports of ownership on Form 3 and changes in ownership on Forms 4 or 5 with the SEC.Such officers, directors and ten percent shareholders are also required by the SEC's rules to furnish ANTARES PHARMA INC with copies of all Section 16(a) reports they file. Specific due dates for such reports have been established by the SEC and ANTARES PHARMA INC is required to disclose any failure to file reports by such dates.Based solely on a review of the copies of such reports received by ANTARES PHARMA INC or by written representations from certain reporting persons, ANTARES PHARMA INC believes that during the year ended December 31, 2001, all Section 16(a) filing requirements applicable to officers, directors and ten percent shareholders were met.

Similar Profiles

Other People with this Name

Other people with the name Rinderknecht

Andrea Rinderknecht
Cincinnati Children's Hospital Medical Center

Randy Rinderknecht
Key Bank

Dana Rinderknecht
Community First Foundation

Jakob Rinderknecht
University of the Incarnate Word

Mati Rinderknecht
Utah High School Rodeo Association

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory